Quest Diagnostics Is Worthy Of More Attention

After nearly two years of flat to falling revenue, it's just plain difficult for Quest Diagnostics (NYSE: DGX  ) to get any positive attention, especially with the black cloud of reimbursement uncertainty hanging over its industry. To end the year, shares of BRCA test pioneers Myriad Genetics (NASDAQ: MYGN  ) were clobbered after a price readjustment from the Centers of Medicare and Medicade Services. The market has let shares of Quest fall to their lowest level in over two years. This could be an opportunity to pick up a great company at a very attractive price.

Read the full article only at The Motley Fool, here.

Tooting my horn

This is beginning to get a little scary. On the day I submitted this article claiming that fears were already priced in, one of the big fears came true. Shares of Myriad Genetics (NASDAQ: MYGN) immediately tanked, If someone had read my article and bought the day of the knee-jerk reaction they would already be up nearly 20%.
I don't make these sort of investments myself. I can't stomach the volatility. I like to write about them because they get attention. I like to invest in wonderfully dull companies with steady predictable growth. This time I wish I had followed my advice.